Business Wire

EDWARDS-LIFESCIENCES

8.6.2023 18:31:26 CEST | Business Wire | Press release

Share
Edwards Lifesciences: Improving Patient Safety and Outcomes: EU-HYPROTECT Registry Demonstrates Reduced Time in Hypotension During Surgery Using Acumen HPI Software

Edwards Lifesciences today announced the results of the EU-HYPROTECT registry which indicates that using Acumen HPI software may help reduce the duration and severity of intraoperative hypotension in patients having non-cardiac surgery.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230608005565/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graph: Business Wire)

EU-HYPROTECT is a European multicenter prospective observational registry which included in its final analysis 702 patients scheduled for elective major non-cardiac surgery in 12 medical centers in 5 countries (France, Germany, Italy, Spain, UK). It is the first multicenter registry involving a predictive monitoring technology, establishing a large, prospectively collected data base on hypotension management in patients having non-cardiac surgery. All patients had intraarterial blood pressure monitoring with an arterial catheter and intraoperative Acumen HPI software.

Both the duration and severity of intraoperative hypotension are associated with postoperative complications. The primary endpoint of this registry, therefore, was intraoperative hypotension quantified using the time-weighted average mean arterial pressure (MAP) <65 mmHg. Secondary endpoints included the proportion of patients with at least one ≥1-min-episode of a MAP <65 mmHg, and the number of ≥1-min-episodes of a MAP <65 mmHg.

Between September 2021 and May 2022, 749 patients were enrolled in the registry and 702 included in the final analysis. The median time-weighted average MAP <65 mmHg was 0.03 (0.00, 0.20) mmHg. 285 patients (41%) had no ≥1-min-episode of a MAP <65 mmHg – 417 patients (59%) had at least one. The median number of ≥1-min-episodes of a MAP <65 mmHg was 1 (0, 3).

In addition, although the study was not powered for this outcome, the incidence of acute kidney injury was at the lower end of what is reported in patients having major non-cardiac surgery.

In Europe, of the 2.5 million patients undergoing high-risk surgery annually, one in four develops serious postoperative complications1,2. Throughout the hospital patient journey, anaesthetists and intensivists need to analyse large amounts of data to make life-critical decisions for patients. One example is critical drops in blood pressure known as hypotension. Intraoperative hypotension is common in patients having non-cardiac surgery under general anaesthesia3. Intraoperative hypotension is associated with increased mortality and major postoperative complications (myocardial injury, acute kidney injury)(4-8).

These postoperative complications come with a significant cost burden for healthcare systems as they are linked with rehospitalisations and increased morbidity.9

Avoiding intraoperative hypotension is a complex task for anesthetists. Current hypotension treatment is mainly reactive, sometimes only being initiated after the blood pressure has already dropped below safe levels”, explains Prof. Bernd Saugel (Hamburg, Germany).

Edwards Lifesciences has developed the Acumen HPI software, which provides clinicians with information regarding the likelihood that a patient will develop hypotension. Based on an algorithm that calculates data from hemodynamic monitoring in perioperative management, it leverages predictive analytics to alert clinicians of potential blood pressure drops before they occur.

“Predictive hemodynamic monitoring may be a promising approach to help clinicians better manage hypotension. It is intriguing to investigate innovations that can support clinicians in clinical decision making and potentially improve quality of care,” comments Prof. Bernd Saugel (Hamburg, Germany).

“The consequences of the COVID-19 pandemic have drastically accelerated the need for solutions that improve patient safety and outcomes, reduce hospital length of stay and increase hospital efficiencies. The results of the EU-HYPROTECT registry are promising and demonstrate the need to better monitor hypotension in the perioperative pathway. Improving patient safety and outcomes is our ultimate goal and we believe the use of predictive monitoring can help achieve this.” comments Pr Thomas Scheeren, Senior Director Medical Affairs EMEACLA at Edwards Lifesciences.

The full results of the EU-HYPROTECT registry were published in the British Journal of Anaesthesia and can be consulted on https://www.bjaopen.org/article/S2772-6096(23)00019-9/fulltext

About Edwards Lifesciences

Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit www.Edwards.com and follow us on Twitter @EdwardsLifesci.

Edwards, Edwards Lifesciences, the stylized E logo, Acumen, Acumen HPI, HPI and Hypotension Prediction Index are trademarks of Edwards Lifesciences Corporation and its affiliates. All other trademarks are the property of their respective owners. This statement is made on behalf of Edwards Lifesciences Corporation and its subsidiaries.

###

References:

1Preoperative Score to Predict Postoperative Mortality – POSPOM Edward’s Presentation

2Ghaferi AA et al. Variation in hospital mortality associated with inpatient surgery. N Engl J Med, 2009.

3Bijker JB, van Klei WA, Kappen TH, van Wolfswinkel L, Moons KG, Kalkman CJ: Incidence of intraoperative hypotension as a function of the chosen definition: literature definitions applied to a retrospective cohort using automated data collection. Anesthesiology 2007, 107(2):213-220.

4Gregory A, Stapelfeldt WH, Khanna AK, Smischney NJ, Boero IJ, Chen Q, Stevens M, Shaw AD: Intraoperative Hypotension Is Associated With Adverse Clinical Outcomes After Noncardiac Surgery. Anesth Analg 2020.

5Salmasi V, Maheshwari K, Yang D, Mascha EJ, Singh A, Sessler DI, Kurz A: Relationship between Intraoperative Hypotension, Defined by Either Reduction from Baseline or Absolute Thresholds, and Acute Kidney and Myocardial Injury after Noncardiac Surgery: A Retrospective Cohort Analysis. Anesthesiology 2017, 126(1):47- 65

6Sessler DI, Khanna AK: Perioperative myocardial injury and the contribution of hypotension. Intensive care medicine 2018, 44(6):811-822

7Sun LY, Wijeysundera DN, Tait GA, Beattie WS: Association of Intraoperative Hypotension with Acute Kidney Injury after Elective Noncardiac Surgery. Anesthesiology 2015, 123(3):515-523.

8Walsh M, Devereaux PJ, Garg AX, Kurz A, Turan A, Rodseth RN, Cywinski J, Thabane L, Sessler DI: Relationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery: toward an empirical definition of hypotension. Anesthesiology 2013, 119(3):507-515

9Vonlanthen R, Slankamenac K, Breitenstein S, Puhan MA, Muller MK, Hahnloser D, Hauri D, Graf R, Clavien PA. The impact of complications on costs of major surgical procedures: a cost analysis of 1200 patients. Ann Surg. 2011 Dec;254(6):907-13. doi: 10.1097/SLA.0b013e31821d4a43. PMID: 21562405.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230608005565/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Secures €50M Financing to Accelerate Global Growth30.3.2026 08:00:00 CEST | Press release

€50 million financing package from funds and accounts managed by BlackRock will support IQM to scale operations, accelerate product development, and strengthen its market position. The facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing as IQM prepares for public listing. IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), today announced it has secured a €50 millionfinancing package from funds and accounts managed by BlackRock. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329996942/en/ IQM Radiance quantum computer is located in IQM's showroom in Espoo, Finland. This facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing. This

Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations30.3.2026 07:45:00 CEST | Press release

Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/ Addressing Critical Trade Finance Challenges The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges. In

Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release

~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye